Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients

BACKGROUND: The prognosis of patients with advanced gastrointestinal stromal tumor (GIST) has improved greatly after the introduction of imatinib. However, primary or secondary resistance to imatinib occurs in the majority of patients. Sunitinib is the standard second line treatment in exon-9 mutate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Mahmoud, Jansen-Werkhoven, Thekla M., Ijzerman, Nikki S., den Hollander, Dide, Bleckman, Roos F., Oosten, Astrid W., Desar, Ingrid M. E., Reyners, An K. L., Steeghs, Neeltje, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684294/
https://www.ncbi.nlm.nih.gov/pubmed/36374447
http://dx.doi.org/10.1007/s11523-022-00926-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684294/
https://www.ncbi.nlm.nih.gov/pubmed/36374447
http://dx.doi.org/10.1007/s11523-022-00926-6

Ejemplares similares